No Slide Title · June 2016 £’000 June 2015 £’000 Balance Sheet - highlights Cash at bank **...
29
Transcript of No Slide Title · June 2016 £’000 June 2015 £’000 Balance Sheet - highlights Cash at bank **...
2
6
7
8
June 2016£’000
June 2015£’000
Loss from Continuing operations (6,121) (4,356)
Loss from Discontinued operations (258) (961)
Loss for the year (6,379) (5,317)
Loss from Continuing operations
R&D (3,730) (2,961)
G&A (2,403) (1,462)
Other costs (413) (93)
Tax credit/Income 425 160
(6,121) (4,356)
June 2016£’000
June 2015£’000
Balance Sheet - highlights
Cash at bank ** 15,931 11,057
Investment in PDS 1,757 1,757
Net assets 18,881 13,542
** Balance as at 31 March 2016 - £19.5m
Cash flow
Funds used in operations (7,191) (5,323)
Other (409) (515)
Increase/(decrease) in cash (7,600) (5,838)
Sector Diagnostics – Respiratory
Source Queen’s University Belfast
Technology Proprietary ProteaseTag™
Product ELISA Cystic Fibrosis testNEATstik point-of-care device
Business Model Product development and licensingContract development with pharma industry
Stage Early commercialisation for ELISA product
Market DriversPharma interest in activated proteasesIncrease self monitoring for chronic diseaseIncreasing incidence in respiratory disease
% Shareholding 57%
Total Investment £0.78m
Grant Funding £1.0
Patent families 1
Sector Diagnostics – Liver
Source Drexel University
Technology Fucosylated protein biomarkers
Product Immunoassay biomarker panels
Business Model Laboratory developed test sales
Stage Pre-commercialisation
Market DriversObesity on-setLarge growth in at risk population due to fatty liver disease
% Shareholding 88%
Total Investment £1.8m
Grant Funding £5.9m
Patent families 3 (1 granted)
PDS Biotechnology altering the landscape of
immunotherapies
Sector Therapeutics – Cancer
Source University of Pittsburgh
Technology Novel cancer immunotherapy
Product Versamune®
Business Model Partner with big pharma
Stage Phase II
Market DriversGrowth in cancer incidence
Need for effective alternative to chemotherapy
% Shareholding 14.85%
Total Investment £2.1m
Grant Funding £3.0m
Patent families 4 (pending)
Versamune® : Potential For More Effective and Safer Immunotherapies
Versamune® has advantages over other immunotherapy technologies
Generate
tumor-specific
killer T-cells
Induce T-cell
activating
cytokines
Block/Reduce
Immune
Suppressors
Checkpoint
Inhibitors
Engineered T-cells
Live Viruses etc.
Delivery Systems
Adjuvants
Versamune®
Sector Digital Health / Wearables
Source Breakout Labs
Technology Non-invasive GI monitoring system
Product Wireless three patch device
Business Model Partnerships
Stage Developmental
Market DriversGrowing incidence of GI issues
Need for more specific diagnosis
% Shareholding Convertible note
Total Investment $0.25m
Patent families 6 (pending)
48
Current long, expensive, invasive, really unpleasant paradigm
History and physical exam
History and physical exam
Alarm symptoms
?
Personalized treatment
Anatomic test
$$$
Anatomic test
$$$
After G-Tech introduction
Sector Digital Health / Wearables
Source Breakout Labs
TechnologyBiomodule to measure autonomic nervous system
through galvanic skin response
ProductDevices and software applications
Bio modules to add to watches / jewellery
Business Model Device sales
Stage Developmental
Market Drivers Demand for self diagnosis
% Shareholding Convertible note
Total Investment $0.35m
Patent families 1 (pending)
Sector Therapeutics – Regenerative Medicine
Source Breakout Labs
Technology Bioreactor platform
Product Custom-designed autologous bone grafts
Business Model Partnerships
Market Drivers Need for functional, patient specific bone implants
% Shareholding Convertible note
Total Investment $0.25m
Grant Funding $2.6m
Patent families 2 (pending)
ff
Sector Therapeutics
Source Breakout Labs
Technology Artificial protein therapy
Product Hybridtides®
Business Model Licensing
Stage Developmental
Market Drivers Increasing efficiency in small molecule drug delivery
% Shareholding Convertible note
Total Investment $0.25m
Patent families 6 (pending)
Sector Diagnostic
Source Breakout Labs
TechnologyMicrofluidic channel to measure subtle cell property
changes
Product Bench top instrument
Business Model
Instrument sales and recurring revenue from
microfluidic chips and consumables
Stage Developmental
Market DriversWide range of opportunities in research tool arena as
well as diagnostics
% Shareholding 2.15%
Total Investment $0.25m
CytoVale’s Solution
Benchtop Instrument Single Use Disposable Cartridge
Rapid, Label-free Analysis of Over 2000 cells / Second
